DNA sequence that causes severe cases of lupus identifiedLabmate OnlineTherapies currently used are based on cortisone, anti-malarial drugs and immunosuppressants (azathioprine, mycophenolate, cyclophosphamide) and biologic drugs (rituximab, Belimumab)…
A genetic accelerator hits the gas on autoimmune diseasesEurekAlert (press release)The therapies currently used are based on cortisone, anti-malarial drugs and immunosuppressants (azathioprine, mycophenolate, cyclophosphamide) and biologic drugs (ritux…
Medications Used to Treat Rheumatoid ArthritisMSN Health & FitnessBiologic DMARDs include etanercept, infliximab, and rituximab. DMARDs almost always require careful monitoring for side effects. Read more about DMARDs here. NSAIDs include familiar over…
Seattle Genetics Sees Updated Side Effect Warning in Drug LabelXconomySeveral new biotech drugs have been linked to cases of PML, including Roche and Biogen Idec's hit lymphoma drug rituximab (Rituxan). The Seattle Genetics drug is designed to hit …
Biogen Idec prepares for multiple launches in coming yearsThe Pharma Letter… which will both have data readouts this year. o Delivering the data readout from the first Phase III trial of dexpramipexole in ALS by year-end. o Continuing to advance the …
PDL BioPharma's CEO Presents at 30th Annual JP Morgan Healthcare Conference …Seeking AlphaDaclizumab is a product which is now jointly owned between Abbott and Biogen Idec for multiple sclerosis. They reported some very nice data from one of thei…
Cyclacel Provides Corporate Update at OneMedForum ConferenceMarketWatch (press release)Commenced an investigator-initiated, Phase 2 trial of sapacitabine in combination with cyclophosphamide and rituximab in patients with previously treated chronic lym…
Biogen Idec presenta sus prioridades estratégicas para 2012 en el 30º Congreso …Business Wire (Comunicado de prensa)Seguir avanzando el programa de Fase 3 de daclizumab sobre EM. La creación de equipos científicos de tipo mundial en sus áreas te…
Emergent BioSolutions' President Presents at the 30th Annual J.P. Morgan …Seeking AlphaCD20 as you may know is a validated target for certain marketed products including Rituximab. This product is completely out-licensed to Pfizer. So Pfizer is r…
Biogen Idec Presents 2012 Strategic Priorities at 30th Annual J.P. Morgan …EON: Enhanced Online News (press release)Continuing to advance the daclizumab Phase 3 program in MS. Building world-class scientific teams in its core therapeutic areas. Advan…